SRTA

Strata Critical Medical Inc

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 90%
Negative

Neutral
GlobeNewsWire
21 hours ago
Strata Acquires Louisville Perfusion Services
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. (“LPS”), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. “The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States,” said Lou Verdetto, CEO of Strata's Clinical Division.
Strata Acquires Louisville Perfusion Services
Neutral
GlobeNewsWire
26 days ago
Strata Critical Medical Announces Expiration of Warrants
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), announced that its warrants, both the Public Warrants (Nasdaq: SRTAW) and the Private Placement Warrants, expired in accordance with their original terms at 5:00 p.m. Eastern Time today May 7, 2026.
Strata Critical Medical Announces Expiration of Warrants
Neutral
Seeking Alpha
27 days ago
Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
27 days ago
Strata Critical Medical Announces First Quarter 2026 Results
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the first quarter ended March 31, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only. The results of the divested Passenger business have been reclassified as discontinued operations in all periods.
Strata Critical Medical Announces First Quarter 2026 Results
Neutral
GlobeNewsWire
1 month ago
Strata Acquires Ohio Valley Perfusion Associates
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced that it has completed the acquisition of Ohio Valley Perfusion Associates ("OVPA"), a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania. “Expanding our presence in Eastern Ohio and Western Pennsylvania is an important step in strengthening Strata's regional clinical platform,” said Louis Verdetto, CEO of Strata's Clinical Services Division.
Strata Acquires Ohio Valley Perfusion Associates
Neutral
GlobeNewsWire
1 month ago
Strata Critical Medical Schedules First Quarter 2026 Earnings Conference Call
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the first quarter ended March 31, 2026 on Wednesday May 6, 2026 before the market opens.
Strata Critical Medical Schedules First Quarter 2026 Earnings Conference Call
Neutral
GlobeNewsWire
1 month ago
Strata Critical Medical to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 1:30 pm ET. A webcast of the event will be available at the link here.
Strata Critical Medical to Present at the 25th Annual Needham Virtual Healthcare Conference
Positive
Seeking Alpha
2 months ago
Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth
Strata Critical Medical is rated 'Buy' with a 12–24 month horizon, targeting 30–35% upside as valuation remains attractive despite a recent rally. SRTA's transformation into a pure-play medical logistics provider, robust FY25 results, and margin expansion underpin confidence in forward guidance. Industry tailwinds, regulatory catalysts, and an aggressive acquisition strategy position SRTA for sustained revenue and EBITDA growth, with FY26 guidance implying an 11.6% EBITDA margin.
Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth
Neutral
Seeking Alpha
3 months ago
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
Strata Critical Medical Announces Fourth Quarter 2025 Results
Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025 Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic growth Full year 2025 net loss from continuing operations was $20.1 million Full year 2025 revenue and Adjusted EBITDA (1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance range Raising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million (2) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the fourth quarter ended December 31, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
Strata Critical Medical Announces Fourth Quarter 2025 Results